Efficacy and safety of upadacitinib in treating immune drift: a single-center, prospective study in China

• by Wanyan Xiang, Jiarong Lu, Siqi Zhang, Wenjun Zheng, Qiuju Li

• July 6, 2026

Modified Delphi Consensus Recommendations for the Management of Psoriasis in Asia–Pacific

• by Yoo Sang Baek, Siew Eng Choon, Peter Anthony Foley, Tsen Fang Tsai, Jianzhong Zhang, Yukie Yamaguchi

• July 1, 2026

Connected Health May Match In-Person AD Care

A randomized clinical trial found that a team-based connected health model achieved equivalent improvements in atopic dermatitis severity and symptoms compared with conventional in-person care over 12 months.

• by Andrea Surnit

• July 9, 2026

• 3 min

FDA Approves Pediatric Risankizumab

Approval expands risankizumab use to pediatric plaque psoriasis and psoriatic arthritis and includes a new 55-mg prefilled syringe for weight-based dosing in patients weighing less than 40 kg.

• by Kathryn Wighton

• June 29, 2026

• 3 min